
    
      An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the
      safety and pharmacokinetics characteristics after administration of fixed dose combination or
      loose combination of AK-R215 in healthy adult male or menopausal female volunteers
    
  